Provided by Tiger Trade Technology Pte. Ltd.

INVESCO PHARMACEUTICALS ETF

124.96
+0.87040.70%
Volume:13.89K
Turnover:1.74M
Market Cap:546.08M
PE:6.48
High:125.72
Open:125.36
Low:124.95
Close:124.09
52wk High:131.68
52wk Low:90.01
Shares:4.37M
Float Shares:4.37M
Volume Ratio:0.55
T/O Rate:0.32%
Dividend:1.06
Dividend Rate:0.85%
EPS(TTM):19.29
EPS(LYR):21.73
ROE:23.89%
ROA:0.60%
PB:1.64
PE(LYR):5.75

Loading ...

Amgen Stock Poised for Worst Day in More than Two Decades

Dow Jones
·
Sep 09

Eli Lilly Stock (LLY) Falls on Competitor Novartis’ Cholesterol Drug Setback

TIPRANKS
·
Sep 09

Top Midday Decliners

MT Newswires Live
·
Sep 09

U.S. Stocks on the MOVE-Best Buy, Peloton, Apple

Reuters
·
Sep 09

Amgen's Olpasiran May Still Show Heart-Risk Reduction Despite Novartis Miss, UBS Says

MT Newswires Live
·
Sep 09

Royalty Pharma Falls After Novartis' Cholesterol Drug Fails in Study

Reuters
·
Sep 09

Amgen Pulls Dow Industrials Lower; Oil Jumps on Houthi Strikes in Saudi Arabia

Dow Jones
·
Sep 09

Top Midday Stories: GE Aerospace to Acquire Consolidated Precision Products; Qualcomm Issues Share Warrant to Amazon

MT Newswires Live
·
Sep 08

NASDAQ Top and Bottom Performing Stocks at About 11:01 A.m. EDT on 2026-09-08

Reuters
·
Sep 08

Amgen Says Phase 3 Study Meets Primary Endpoint in Small Cell Lung Cancer

MT Newswires Live
·
Sep 08

Amgen Inc Stock (AMGN) Moved Down by 8.33% on Sep 8: A Full Analysis

TradingKey
·
Sep 08

U.S. Stocks on the MOVE-Sigma Lithium, Shake Shack, Novartis

Reuters
·
Sep 08

Dow Drops 438 Points on Losses for Amgen, Salesforce Shares

Dow Jones
·
Sep 08

Amgen Down Nearly 7%, on Pace for Largest Percent Decrease Since March 2020

Dow Jones
·
Sep 08

Amgen-AstraZeneca Cancer Drug Combo Hits Main Survival Goal in Late-Stage Trial

Reuters
·
Sep 08

AstraZeneca announces results from Phase III trial of IMFINZI, tarlatamab

TIPRANKS
·
Sep 08

Amgen - Phase 3 Dellphi-305 Study Delivers Significant Overall Survival Benefit Versus Durvalumab Alone

THOMSON REUTERS
·
Sep 08

Imdelltra® in Combination with Imfinzi® Demonstrated Landmark Improvement in Overall Survival in First-Line Extensive Stage Small Cell Lung Cancer

THOMSON REUTERS
·
Sep 08

Amgen - Study Meets Secondary Endpoints for Progression-Free Survival and Objective Response Rate

THOMSON REUTERS
·
Sep 08

Amgen - no New or Unexpected Safety Signals Identified in Dellphi-305 Study

THOMSON REUTERS
·
Sep 08